# Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 11054 CL Administered With the Respimat® in Healthy Male Volunteers

> **NCT02273401** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 96 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 11054 CL
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02273401
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2008-08
- **Final completion:** —
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2014-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02273401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02273401, "Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 11054 CL Administered With the Respimat® in Healthy Male Volunteers". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT02273401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*